The trial will test dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with standard clinical evaluation in patients with pancreatic ductal adenocarcinoma that involves arteries or veins near the pancreas but can be removed with the right treatment beforehand. DCE-MRI measures blood perfusion in the tumor, which can show disease status.
The study will enroll 50 participants and is led by Shafia Rahman, M.D., a medical oncologist at the OSUCCC—James. The tool was developed at the OSUCCC—James in partnership with Harrison Kim, Ph.D., a radiology scientist and director of the Quantitative Medical Imaging Laboratory.